论文部分内容阅读
目的观察妇女孕前抗病毒治疗并联合孕后乙型肝炎免疫球蛋白(HBIG)对宫内感染率的影响。方法选取114例乙肝母婴传播阻断门诊HBsAg/HBeAg双阳性育龄妇女及其所生婴儿,分为3组即联合阻断组:接受孕前拉米夫定和苦参素治疗并孕后24周HBIG阻断;阻断组:仅接受孕后24周HBIG阻断;对照组:未采用孕前及孕后阻断措施。所有新生儿在产后即刻取外周静脉血查HBV-M及HBV DNA检测,以发现官内感染者。结果三组观察对象的宫内感染率有所不同,对照组宫内感染率为22．2％,阻断组感染率为13．3％,联合阻断组宫内感染率为7．89％,较阻断组的宫内感染率为低。结论孕前抗病毒治疗和孕后乙肝免疫球蛋白联合措施,可将HBsAg/ HBeAg双阳性孕妇的宫内感染率进一步降低。
Objective To observe the effect of pre-pregnancy antiviral therapy combined with hepatitis B immunoglobulin (HBIG) on intrauterine infection in women. Methods A total of 114 HBsAg / HBeAg-positive women of childbearing age and their infants were randomly divided into three groups: the combined blockade group: receiving lamivudine and oxymatrine before pregnancy and 24 weeks after conception HBIG block; block group: HBIG block only accepted 24 weeks after pregnancy; control group: did not use pre-pregnancy and post-pregnancy block measures. All newborns in the immediate postpartum peripheral venous blood to check HBV-M and HBV DNA testing to find the official infection. Results The intrauterine infection rates of the three groups were different. The intrauterine infection rate in control group was 22.2%, the infection rate in blocking group was 13.3%, the intrauterine infection rate in combined blocking group was 7.89% , More than intrauterine infection blocking group was low. Conclusion Pre-pregnancy antiviral therapy and post-pregnancy hepatitis B immunoglobulin joint measures, HBsAg / HBeAg double positive pregnant women with intrauterine infection rates further reduced.